4.3 Article

The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors

Journal

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
Volume 25, Issue 6, Pages 411-415

Publisher

SAGE PUBLICATIONS INC
DOI: 10.2500/ajra.2011.25.3660

Keywords

-

Ask authors/readers for more resources

Background: Aspirin (acetylsalicylic acid [ASA]) hypersensitivity is frequent in patients with nasal polyps (NPs) and is called aspirin exacerbated respiratory disease, previously known as Samter's syndrome. However, studies evaluating the prevalence of ASA hypersensitivity in patients with NPs using the oral aspirin provocation test (APT) are quite limited. This study was designed to determine the prevalence of ASA hypersensitivity and factors associated with ASA hypersensitivity in patients with NPs. Methods: Sixty-eight patients with NPs with or without asthma were recruited. Extension of NPs was evaluated by endoscopic examination/paranasal CT. A 2-day, single-blind placebo-controlled APT was used to detect ASA hypersensitivity. Results: APT was performed in 53 (21 women/32 men) patients (mean age, 39.34 +/- 1.76 years). APT resulted positive in 12 patients (22.6%) of whom 3 (25%) had no history of ASA hypersensitivity. Of the positive APTs, three were isolated rhinitis and nine had classic responses. APT was negative in 41 patients (77.4%) although three (7.3%) had a history of ASA hypersensitivity. History of ASA hypersensitivity and prolonged duration of NPs were associated with positive APT (p < 0.05). Advanced NP with multiple operations was also correlated with APT positivity but was not statistically significant. Presence of asthma was associated with age, female gender, NP duration, and ASA hypersensitivity history (p < 0.05), but not with smoking, atopy, NP extension, and positive APT. Conclusion: ASA hypersensitivity is quite common in patients with NP. Patients with extensive and long-term NP with multiple polyp operations require evaluation for the presence of ASA hypersensitivity in terms of chronic management and future risks of the disease. (Am J Rhinol Allergy 25, 411-415, 2011; doi:10.2500/ajra.2011.25.3660)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Allergy

Hypersensitivity reactions to biologicals: An EAACI position paper

Sevim Bavbek, Mauro Pagani, Emilio Alvarez-Cuesta, Mariana Castells, Adile Berna Dursun, Sahar Hamadi, Ricardo Madrigal-Burgaleta, Soledad Sanchez-Sanchez, Alessandra Vultaggio

Summary: Biologicals are important therapeutic agents for oncological, immunological, and inflammatory diseases, but they can cause hypersensitivity reactions. The optimal management pathways for these reactions are still uncertain.

ALLERGY (2022)

Article Allergy

Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper

Annick Barbaud, Lene Heise Garvey, Alessandra Arcolaci, Knut Brockow, Francesca Mori, Cristobalina Mayorga, Patrizia Bonadonna, Marina Atanaskovic-Markovic, Luis Moral, Giovanna Zanoni, Mauro Pagani, Angele Soria, Maja Jost, Jean-Christoph Caubet, Abreu Carmo, Al-Ahmad Mona, Alberto Alvarez-Perea, Sevim Bavbek, Biagioni Benedetta, M. Beatrice Bilo, Natalia Blanca-Lopez, Herrera Gador Bogas, Alessandro Buonomo, Gianfranco Calogiuri, Giulia Carli, Josefina Cernadas, Gabriele Cortellini, Gulfem Celik, Semra Demir, Inmaculada Dona, Adile Berna Dursun, Bernadette Eberlein, Emilia Faria, Bryan Fernandes, Tomaz Garcez, Ignacio Garcia-Nunez, Radoslaw Gawlik, Asli Gelincik, Eva Gomes, Jimmy H. C. Gooi, Martine Grosber, Theo Gulen, Florence Hacard, Cyrille Hoarau, Christer Janson, Sebastian L. Johnston, Lukas Joerg, Secil Kepil Ozdemir, Ludger Klimek, Mitja Kosnik, Marek L. Kowalski, Semanur Kuyucu, Violeta Kvedariene, Jose Julio Laguna, Carla Lombardo, Susana Marinho, Hans Merk, Elisa Meucci, Martine Morisset, Rosa Munoz-Cano, Francesco Murzilli, Alla Nakonechna, Florin-Dan Popescu, Grzegorz Porebski, Anna Radice, Frederico S. Regateiro, Heike Rockmann, Antonino Romano, Ravishankar Sargur, Joaquin Sastre, Kathrin Scherer Hofmeier, Lenka Sedlackova, Marta Sobotkova, Ingrid Terreehorst, Regina Treudler, Jolanta Walusiak-Skorupa, Bettina Wedi, Stefan Wohrl, Mihael Zidarn, Torsten Zuberbier, Ioana Agache, Maria J. Torres

Summary: Background anaphylaxis after COVID-19 vaccination is rare, and its management is not standardized. The authors propose allergy evaluation and prick test for individuals with specific allergy histories, aiming to improve the understanding and management of anaphylaxis to COVID-19 vaccines and facilitate vaccination for people with allergy history.

ALLERGY (2022)

Article Allergy

Hypersensitivity reactions to chemotherapy: an EAACI Position Paper

Mauro Pagani, Sevim Bavbek, Emilio Alvarez-Cuesta, Adile Berna Dursun, Patrizia Bonadonna, Mariana Castells, Josefina Cernadas, Anca Chiriac, Hamadi Sahar, Ricardo Madrigal-Burgaleta, Soledad Sanchez Sanchez

Summary: Chemotherapeutic drugs can induce hypersensitivity reactions, being the third leading cause of fatal drug-induced anaphylaxis. Deaths related to chemotherapy have been reported in Europe and the United States. The European Network on Drug Allergy organized a task force to provide data and recommendations regarding allergological work-up in this field.

ALLERGY (2022)

Article Allergy

Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data

Betuel oezdel oeztuerk, Zeynep Yavuz, Dilek Eraslan, Dilsad Mungan, Yavuz Selim Demirel, Oemuer Aydin, Betuel Ayse Sin, Sevim Bavbek

Summary: The study shows that mepolizumab effectively helps patients with severe eosinophilic asthma improve asthma control, reduce exacerbation frequency, lower steroid usage, enhance lung function and quality of life.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2022)

Article Allergy

Rapid drug desensitization with platin-based chemotherapy: Analysis of risk factors for breakthrough reactions

Begum Gorgulu Akin, Merve Erkoc, Elif Tugce Korkmaz, Betul Ozdel Ozturk, Sevgi Colak, Funda Seher Ozalp Ates, Sevim Bavbek

Summary: In this study, we investigated patients with platinum allergy and validated the effectiveness of the rapid drug desensitization protocol. The results showed that a positive drug skin test result can serve as a potential marker for identifying high-risk patients who may experience breakthrough reactions during desensitization.

WORLD ALLERGY ORGANIZATION JOURNAL (2022)

Article Allergy

Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19

Merve Erkoc, Betel Ozdel Ozturk, Dilsad Mungan, Derya Oztuna, Sevim Bavbek, Yavuz Seim Demirel, Omiir Aydin, Sethi Aye Sin

Summary: COVID-19 pandemic has affected compliance to AIT, but no severe COVID-19 infection or related deaths were observed in patients receiving AIT. Compliance rate for AIT was highest in venom immunotherapy.

ASIA PACIFIC ALLERGY (2022)

Article Allergy

Comparison of two diagnostic criteria in the diagnosis of anaphylaxis in a tertiary adult allergy clinic

Sevgi Colak, Merve Erkoc, Betuel A. Sin, Sevim Bavbek

Summary: This study retrospectively analyzed cases diagnosed with anaphylaxis and compared the diagnostic criteria proposed by NIAID/FAAN and WAO. The results showed that the main causes of anaphylaxis were drugs, venom, and food allergies, with chemotherapeutics being the most common drug trigger. According to the NIAID/FAAN criteria, most patients were diagnosed with the second criterion, while according to the WAO criteria, most patients were diagnosed with the first criterion. The study suggests that collecting more details in patients' history can prevent possible underdiagnosis, and the WAO diagnostic criteria may be insufficient in some patients.

WORLD ALLERGY ORGANIZATION JOURNAL (2023)

Article Multidisciplinary Sciences

Relationship between aeroallergen sensitization pattern and clinical features in adult asthmatics

Dilek Karadogan, Tahsin Gokhan Telatar, Halil Donmez, Adile Berna Dursun

Summary: This study examined the relationship between aeroallergen sensitivity and disease control level and severity in asthmatic patients. The results showed that polysensitized asthmatics had better asthma symptom control and milder asthma severity compared to monosensitized asthmatics. However, there was no significant association between aeroallergen sensitivity and asthma control level.

HELIYON (2023)

Review Respiratory System

Biologics for the treatment of severe asthma: Current status report 2023

Gulden Pacaci Cetin, Secil Kepil Ozdemir, Ozge Can Bostan, Nida Oztop, Zeynep Celebi Sozener, Gul Karakaya, Asli Gelincik Akkor, Insu Yilmaz, Dilsad Mungan, Sevim Bavbek

Summary: Severe asthma burdens patients and societies with increased healthcare use, decreased quality of life, and high disease and economic burden. Approved biological agents, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, have been shown to effectively reduce asthma exacerbations, oral corticosteroid use, and improve asthma control, quality of life, and pulmonary functions in severe asthma through targeting cells, receptors, and mediators involved in type 2 inflammation. Personalized treatment based on the characterization of asthma endotype and phenotype is crucial for determining the appropriate biologic agent for individual patients.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX (2023)

Letter Allergy

Apples and pears serve the same purpose: Better diagnosis for anaphylaxis

Sevgi Colak, Merve Erkoc, Betuel A. Sin, Sevim Bavbek

WORLD ALLERGY ORGANIZATION JOURNAL (2023)

Article Allergy

Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

Sevim Bavbek, Secil Kepil Ozdemir, Patrizia Bonadonna, Marina Atanaskovic-Markovic, Annick Barbaud, Knut Brockow, Jose Laguna Martinez, Alla Nakonechna, Mauro Pagani, Alessandra Arcolaci, Carla Lombardo, Maria J. Torres

Summary: This paper provides evidence-based recommendations for the diagnosis and management of hypersensitivity reactions (HSRs) to proton pump inhibitors (PPIs), and calls for further in-depth research.

ALLERGY (2023)

Article Allergy

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers

Betul Ozdel Ozturk, Irem Akdemir, Alpay Azap, Gulfem Celik, Sevim Bavbek, Dilsad Mungan

Summary: This study aimed to investigate the rate and features of allergic reactions associated with CoronaVac vaccine among healthcare workers. The results showed that the reaction rate was 0.56%, with the most common reaction being systemic skin reactions. Anaphylaxis was rare, and all cases were discharged within 24 hours.

ASIA PACIFIC ALLERGY (2022)

Meeting Abstract Allergy

Overview of asthma patients followed up in a tertiary clinic

Zeynep Celebi Sozener, Betul Ozdel Ozturk, Omur Aydin, Sevim Bavbek, Dilsad Mungan

CLINICAL AND EXPERIMENTAL ALLERGY (2022)

No Data Available